Passa al contenuto
Merck
Tutte le immagini(1)

Documenti

B-006

Supelco

Butalbital solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Sinonimo/i:

5-Allyl-5-isobutylbarbituric acid

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C11H16N2O3
Numero CAS:
77-26-9
Peso molecolare:
224.26
Numero MDL:
MFCD00056089
Codice UNSPSC:
41116107
ID PubChem:
329773093
NACRES:
NA.24

Grado

certified reference material

Forma fisica

liquid

Caratteristiche

SNAP-N-SPIKE®, SNAP-N-SHOOT®

Confezionamento

ampule of 1 mL

Produttore/marchio commerciale

Cerilliant®

drug control

Narcotic Licence Schedule B (Switzerland); psicótropo (Spain); Decreto Lei 15/93: Tabela IIC (Portugal)

Concentrazione

1.0 mg/mL in methanol

tecniche

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

applicazioni

forensics and toxicology

Formato

single component solution

Temperatura di conservazione

2-8°C

Stringa SMILE

CC(C)CC1(CC=C)C(=O)NC(=O)NC1=O

InChI

1S/C11H16N2O3/c1-4-5-11(6-7(2)3)8(14)12-10(16)13-9(11)15/h4,7H,1,5-6H2,2-3H3,(H2,12,13,14,15,16)
UZVHFVZFNXBMQJ-UHFFFAOYSA-N

Informazioni sul gene

human ... GABRA1(2554) , GABRA2(2555) , GABRA3(2556) , GABRA4(2557) , GABRA5(2558) , GABRA6(2559) , GABRB1(2560) , GABRB2(2561) , GABRB3(2562) , GABRD(2563) , GABRE(2564) , GABRG1(2565) , GABRG2(2566) , GABRG3(2567) , GABRP(2568) , GABRQ(55879)

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Categorie correlate

Descrizione generale

Butalbital is a barbiturate often combined with other medications such as acetaminophen or aspirin for the treatment of pain or codeine for headaches. Trade names of several butalbital combinations include Axocet®, Bucet, and Bupap® with acetaminophen and Axotal with aspirin. This certified reference solution is suitable for GC/MS or LC/MS applications in forensic analysis, clinical toxicology or urine drug testing.

Applicazioni


  • Butalbital API for Research: Investigates Butalbital as an active pharmaceutical ingredient (API), focusing on its properties and applications in synthesizing complex pharmaceutical formulations, essential for developing new barbiturate-based treatments (Yang et al., 2022).

  • Butalbital Compound Synthesis: Explores the synthesis of Butalbital and its derivatives, underlining its critical role in the development of CNS depressants and its pharmacological potential in neurobiological research (Marmura et al., 2015).

  • Barbiturate Biochemical Research: Focuses on Butalbital′s effects on human platelet aggregation, offering insights into its mechanism of action within the cardiovascular system, which is vital for tailoring barbiturate-based therapies (Sato et al., 2003).

  • Butalbital Pharmacological Studies: Discusses the pharmacological profiling of Butalbital, emphasizing its utility in managing acute pain and headaches, thereby supporting its continued use in clinical settings for migraine and tension headache relief (Mazer-Amirshahi et al., 2014).

  • CNS Depressant Research Chemical: Analyzes Butalbital′s role as a central nervous system depressant, assessing its effectiveness and safety profile, which is crucial for its application in chronic pain management and treatment of cluster headaches (Cutrer et al., 1999).



Note legali

Axocet is a registered trademark of Fougera Pharmaceuticals Inc.
Bupap is a registered trademark of ECR Pharmaceuticals Co., Inc.
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

Avvertenze

Danger

Indicazioni di pericolo

H225,H301 + H311 + H331,H370

Classi di pericolo

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Codice della classe di stoccaggio

3 - Flammable liquids

Classe di pericolosità dell'acqua (WGK)

WGK 1

Punto d’infiammabilità (°F)

49.5 °F - closed cup

Punto d’infiammabilità (°C)

9.7 °C - closed cup

Certificati d'analisi (COA)

Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

Seymour Solomon
Current pain and headache reports, 6(2), 147-150 (2002-03-02)
Butalbital compounds are of proven efficacy in the treatment of tension headache. Decades of experience have established their value in the treatment of other mild-to-moderate headaches. Untold numbers of people rely on these medications as their drug of choice or
W T Chang et al.
Journal of analytical toxicology, 25(8), 659-669 (2002-01-05)
As a part of our study on the use of isotopic analogues as the internal standard (IS) for the quantitation of drug analytes, this article reports on the performance characteristics of 2H5-butalbital and 13C4-butalbital with particular focus on (1) determining
William B Young et al.
Current pain and headache reports, 6(2), 151-155 (2002-03-02)
In the United States analgesic-overuse headache is often caused by butalbital-containing analgesics. These agents can cause physical and psychological dependency, and dangerous withdrawal syndromes. Butalbital-containing analgesics have already been banned in several European countries. They are proven effective in tension-type
Richard G Wenzel et al.
Pharmacotherapy, 22(8), 1029-1035 (2002-08-14)
To evaluate the role of butalbital-containing products in the management of migraine. Qualitative systematic search using MEDLINE (January 1966-November 2001), review of the United States Headache Consortium's evidence-based guidelines for migraine treatment, and review of other pertinent literature. Over 28
Karla A Moore et al.
Forensic science international, 134(2-3), 120-122 (2003-07-10)
Zaleplon ("Sonata") is a pyrazolopyrimidine derivative approved for use in the United States for the treatment of insomnia. To date, there has been little data in the toxicological literature where zaleplon has been implicated as causing a fatal intoxication, either
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.